Influence of baseline renal function and dose reduction of nephrotoxic chemotherapeutic agents on the outcome of metastatic urothelial carcinoma: A retrospective study

International Journal of Urology

Volumn 19, Issue 2, 2012, Pages 110-116

  Maru, Shintaro ^a   Abe, Takashige ^a   Shinohara, Nobuo ^a   Sazawa, Ataru ^a   Maruyama, Satoru ^a   Harabayashi, Toru ^b   Suzuki, Shin ^c   Nonomura, Katsuya ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HOKKAIDO CANCER CENTER   (Japan)

^c KKR Sapporo Medical Center   (Japan)

Author keywords

Bladder cancer; Chemotherapy; Dose dense; Renal impairment; Urothelial carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CREATININE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; GEMCITABINE; IFOSFAMIDE; METHOTREXATE; NEDAPLATIN; PACLITAXEL; VINBLASTINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; CREATININE CLEARANCE; DOSE RESPONSE; DRUG DOSE REDUCTION; FEMALE; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SYSTEMIC THERAPY; TRANSITIONAL CELL CARCINOMA;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, TRANSITIONAL CELL; CREATININE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; JAPAN; MALE; MIDDLE AGED; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES; SURVIVAL RATE; URINARY BLADDER NEOPLASMS;

EID: 84856228989     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2011.02913.x     Document Type: Article

References (13)

1. Marugame T, Kamo K, Katanoda K etal. Cancer incidence and incidence rates in Japan in 2000: estimates based on data from 11 population-based cancer registries. Jpn. J. Clin. Oncol. 2006; 36: 668-75.
2. von der Maase H, Hansen SW, Roberts JT etal. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multi-national, multicenter, phase III study. J. Clin. Oncol. 2000; 17: 3068-77.
3. Kintzel PE, Dorr RT. Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat. Rev. 1995; 21: 33-64.
4. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-14.
5. Therasse P, Arbuck SG, Eisenhauer EA etal. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 2000; 92: 205-16.
6. Abe T, Shinohara N, Harabayashi T etal. Impact of multimodal treatment on survival in patients with metastatic urothelial cancer. Eur. Urol. 2007; 52: 1106-13.
7. Dash A, Galsky MD, Vickers AJ etal. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer 2006; 107: 506-13.
8. Kaag MG, O'Malley RL, O'Malley P etal. Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy. Eur. Urol. 2010; 58: 581-7.
9. Linardou H, Aravantinos G, Efstathiou E etal. Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: phase II study of the Hellenic Cooperative Oncology Group. Urology 2004; 64: 479-84.
10. Vaughn DJ, Malkowicz SB, Zoltick B etal. Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen. J. Clin. Oncol. 1998; 16: 255-60.
11. Bellmunt J, Ribas A, Eres N etal. Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer 1997; 80: 1966-72.
12. Carles J, Nogue M, Domenech M etal. Carboplatin-gemcitabine treatment of patients with transitional cell carcinoma of the bladder and impaired renal function. Oncology 2000; 59: 24-7.
13. Bellmunt J, de WR, Albanell J, Baselga J. A feasibility study of carboplatin with fixed dose of gemcitabine in "unfit" patients with advanced bladder cancer. Eur. J. Cancer 2001; 37: 2212-15.